These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
431 related articles for article (PubMed ID: 19472560)
21. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Leiderman DB Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069 [TBL] [Abstract][Full Text] [Related]
22. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS). Sloan PA J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921 [No Abstract] [Full Text] [Related]
23. In brief: propoxyphene toxicity. Med Lett Drugs Ther; 2010 Sep; 52(1346):69. PubMed ID: 20814401 [No Abstract] [Full Text] [Related]
24. Perspectives. New twist on guideline dissemination stirs professional debate, gets slap from FDA. Newman L Med Health; 1999 Feb; 53(8):suppl 1-4. PubMed ID: 10345551 [No Abstract] [Full Text] [Related]
25. Twenty five years of poison center experience with propoxyphene overdoses the FDA could not find. Hayes BD; Anderson BD Clin Toxicol (Phila); 2009 Nov; 47(9):905-6. PubMed ID: 19814605 [No Abstract] [Full Text] [Related]
26. Oncology nurses at all levels need to know about REMS. Haas ML ONS Connect; 2010 Mar; 25(3):23. PubMed ID: 20344892 [No Abstract] [Full Text] [Related]
29. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act. Cooper DE Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915 [No Abstract] [Full Text] [Related]
30. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education. Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848 [TBL] [Abstract][Full Text] [Related]
31. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex. Epstein RA Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898 [No Abstract] [Full Text] [Related]
32. Pain treatment, drug diversion, and the casualties of war. Burgess F Pain Med; 2006; 7(6):474-5. PubMed ID: 17112360 [No Abstract] [Full Text] [Related]
33. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice. Food and Drug Administration, HHS Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933 [TBL] [Abstract][Full Text] [Related]
34. Drug approval process and FDA. Schmidt AM N Y State J Med; 1976 Nov; 76(12):2039-42. PubMed ID: 1069200 [No Abstract] [Full Text] [Related]
35. FDA committee: More restrictions needed on hydrocodone combination products. Kuehn BM JAMA; 2013 Mar; 309(9):862. PubMed ID: 23462764 [No Abstract] [Full Text] [Related]
36. Letter: FDA and the drug industry. Pitesky I Ann Allergy; 1974 Mar; 32(3):178. PubMed ID: 4405952 [No Abstract] [Full Text] [Related]
37. The danger of imperfect regulation: OxyContin use in the United States and Canada. Lexchin J; Kohler JC Int J Risk Saf Med; 2011; 23(4):233-40. PubMed ID: 22156088 [TBL] [Abstract][Full Text] [Related]